For example, it has been shown that a fusion protein, composed of the truncated diphtheria toxin, IL-2, and an anti-CCR4 antibody generating a bispecific IL2-CCR4 IT, can be used for the treatment of cutaneous T-cell lymphoma (CTCL) [88]. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.